Intelligence / B2B SaaS / Acquisitions / Theravance Biopharma, Inc.
M&Awas acquired (SEC 8-K)23 Sept 2026
Theravance Biopharma, Inc.
23 Sept 2026: Was acquired (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.
- Filed
- 23 Sept 2026
- Ticker
- TBPH
- Role
- Was acquired
- Sector
- Pharma and biotech
- Sic
- 2834
- Items
- 1.01, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
- Summary
- This Current Report on Form 8-K is being filed in connection with the completion on September 23, 2026 of the transactions contemplated by that certain Agreement and Plan of Merger (the " Merger Agreement "), dated as of June 28, 2026, by and among Theravance Biopharma, Inc., an exempted company with limited liability
- Location
- George Town, Grand Cayman, CA
- State
- California
- Country
- United States
- SEC CIK
- 1583107
- Reference
- 0001104659-26-109979
What this signal means
Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.
- Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
- 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS
Find the decision makers at Theravance Biopharma, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.
More in Was acquired
Acquisitions
18 NovImpact Biomedical INC.was acquired (SEC 8-K) · Pharma and biotechM&A6 NovBowman Consulting Group Ltd.was acquired (SEC 8-K) · Business servicesM&A2 NovKenvue Inc.was acquired (SEC 8-K) · ManufacturingM&A2 NovLiveRamp Holdings, Inc.was acquired (SEC 8-K) · Software and ITM&A2 NovSupernus Pharmaceuticals, INC.was acquired (SEC 8-K) · Pharma and biotechM&A26 OctNathans Famous, INC.was acquired (SEC 8-K) · Wholesale and retailM&A
Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.